Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROAD Regimen in Relapsed CD20+ B-Cell NHL
NCT00166439Phase 2Completed
- Sponsor
- Academic and Community Cancer Research United
- Start
- Mar 2005
- Primary completion
- Sep 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in B-cell non-Hodgkin lymphoma, sponsored by Academic and Community Cancer Research United. Primary endpoint: Overall Response Rate After Two Cycles of ROAD at 42 days. Started Mar 2005; status: completed.
02
Drugs
oxaliplatin
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00166439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00166439.